Kenvue Inc. (KVUE)
| Market Cap | 33.12B -25.9% |
| Revenue (ttm) | 15.12B -2.1% |
| Net Income | 1.47B +42.7% |
| EPS | 0.76 +41.3% |
| Shares Out | 1.92B |
| PE Ratio | 22.74 |
| Forward PE | 15.24 |
| Dividend | $0.83 (4.80%) |
| Ex-Dividend Date | Feb 11, 2026 |
| Volume | 10,701,219 |
| Open | 16.81 |
| Previous Close | 16.73 |
| Day's Range | 16.76 - 17.32 |
| 52-Week Range | 14.02 - 25.17 |
| Beta | 0.57 |
| Analysts | Buy |
| Price Target | 19.64 (+13.66%) |
| Earnings Date | May 7, 2026 |
About KVUE
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral a... [Read more]
Financial Performance
In 2025, Kenvue's revenue was $15.12 billion, a decrease of -2.14% compared to the previous year's $15.46 billion. Earnings were $1.47 billion, an increase of 42.72%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for KVUE stock is "Buy." The 12-month stock price target is $19.64, which is an increase of 13.66% from the latest price.
News
Tylenol use among women dropped after Trump tied it to autism
Tylenol use among pregnant women fell after U.S. President Donald Trump linked autism to the over-the-counter pain relief medicine, according to an analysis of U.S. emergency room prescribing patterns...
Judge rejects Kenvue bid to dismiss Texas lawsuit over Tylenol
A Texas judge on Thursday rejected Kenvue's bid to dismiss a lawsuit by that state's Attorney General Ken Paxton accusing the company of concealing autism and other risks to children when pregnant wom...
Kenvue to Cut 3.5% of Workforce Ahead of Kimberly-Clark Deal
The job cuts are part of a restructuring plan to optimize its operating model and drive operational efficiencies, the company said.
Kenvue beats quarterly estimates, announces job cuts amid Kimberly-Clark acquisition
Tylenol-maker Kenvue on Tuesday beat Wall Street estimates for fourth-quarter results and announced a global workforce reduction, as it proceeds toward a planned takeover by Kimberly-Clark.
Kenvue Reports Fourth Quarter and Full Year 2025 Results
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced financial results for the fiscal fourth quarter and full year ended December 28, 2025. “We ended 2025 with stronger top- and bot...
Kenvue to Announce Fourth Quarter and Full Year 2025 Results on February 17, 2026
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce its fourth quarter and full year 2025 financial results after market close on February 17, 2026. Due to the pending transaction wi...
Kimberly-Clark and Kenvue Shareholders Overwhelmingly Approve Kimberly-Clark's Acquisition of Kenvue
Key Milestone in Creating a Global Health and Wellness Leader Transaction Expected to Close in the Second Half of 2026 DALLAS and SUMMIT, N.J., Jan. 29, 2026 /PRNewswire/ -- Kimberly-Clark Corporation...
Kenvue Declares Quarterly Cash Dividend
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock. The quarterly dividend is pa...
Kimberly-Clark Posts Higher Profit Ahead of Kenvue Vote
Kimberly-Clark reported a higher profit in its latest quarter just days before shareholders vote on its plan to buy Kenvue, a deal designed to create a global health-and-wellness giant.
Paracetamol/Tylenol in pregnancy is safe, says research prompted by Trump autism claims
Taking paracetamol, known as Tylenol in the U.S., during pregnancy is safe, a group of European researchers have said, after compiling data in response to U.S. President Donald Trump's claims of a lin...
ISS recommends shareholders approve Kimberly-Clark's planned Kenvue deal
Institutional Shareholder Services on Friday recommended that shareholders approve plans by Kleenex maker Kimberly-Clark to buy Tylenol maker Kenvue, saying a tie-up could improve financial metri...
US appeals court to weigh reviving cases over Tylenol and autism
A U.S. appeals court is expected to hear arguments on Monday from families seeking to revive their lawsuits over Tylenol, after the Trump administration publicly promoted their claims that the popular...
Texas state judge won't block Kenvue from paying dividend, company lawyer says
A Texas state judge won't block Kenvue from paying its scheduled November 26 shareholder dividend, rejecting a request by Texas Attorney General Ken Paxton, a Kenvue lawyer told Reuters on Friday.
Judge to weigh if Texas AG can block Kenvue dividend over Tylenol
A Texas judge on Friday will consider state Attorney General Ken Paxton's bid to block Kenvue from paying a $398 million dividend to shareholders and from marketing Tylenol as safe for pregnant women.
Texas seeks to block Kenvue dividend amid Tylenol lawsuit
Texas Attorney General Ken Paxton on Thursday asked a state judge to block Kenvue from paying a nearly $400 million shareholder dividend this month, after suing the drugmaker for allegedly concealing ...
Kenvue's $48.7 Billion Sale Puts Consumer Staples ETFs Back In Vogue
Consumer staples ETFs, usually the quiet corner of the market, are suddenly in the spotlight. The $48.7 billion acquisition of Kenvue Inc. (NYSE:KVUE) by Kimberly-Clark Corp (NASDAQ:KMB) has stirred r...
The CEO Behind Kimberly-Clark's $40 Billion Gamble on Tylenol Maker
Mike Hsu aims to stoke the consumer company's growth by veering into Kenvue's higher-margin but risky health products.
Kenvue Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kenvue Inc. - KVUE
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ...
Kimberly-Clark CEO talks Kenvue acquisition, calls Tylenol brand 'resilient'
Kimberly-Clark CEO Mike Hsu told CNBC's Jim Cramer that his company's acquisition of Tylenol maker Kenvue will create value for shareholders, even as the the pain reliever is scrutinized by the Trump ...
Kenvue's legal risks loom over planned acquisition by Kimberly-Clark
Kimberly-Clark said on Monday it plans to acquire Band-Aid maker Kenvue , even as the latter company faces thousands of lawsuits involving its painkiller Tylenol and talc-based baby powder, raising qu...
S&P 500 Gains & Losses Today: Amazon Stock Jumps After OpenAI Deal; Kimberly-Clark Acquires Kenvue
A linkup with an artificial intelligence player helped power shares of a top cloud-computing services company higher Monday, while an acquisition in the consumer goods space sent the two stocks on div...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kenvue Inc.
NEW YORK , Nov. 3, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Kenvue Inc. (NYSE: KVUE) and its board of directors concerning the proposed acquisition ...
Kimberly-Clark's $50 billion leap into health and beauty tests investor faith
Kimberly-Clark's nearly $50 billion offer for Tylenol maker Kenvue is a risky bet that the world's biggest consumer market, the United States, will keep growing even as lower-income shoppers trim thei...
KVUE stock price: Kenvue soars 19% today, Kimberly-Clark deal offers a win after Trump Tylenol drama
It's been a tough few weeks for the consumer health company Kenvue, after President Trump publicly spread unproven claims about Tylenol, one of its core subsidiary brands. Today, though, it seems like...
Explainer: Is Tylenol safe to take during pregnancy?
There is no firm evidence of a link between the use of the drug and autism.